REVIEW PAPER

A Structured Strategy for Pharmaceutical Analytical Method Development Based on Quality by Design (Qbd) and Analytical Quality by Design (Aqbd): Core Principles, Methodological Tools, and Regulatory Compliance Considerations

Rihana Syed[1,2*], Rishi Kumar[2], Venkata Rao Vutla[3]

[1] Research Scholar, School of Pharmacy, Raffles University, Neemrana - 301705; Department of Pharmaceutical Analysis, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Guntur, A.P., India - 522019.

[2] Associate Professor, School of Pharmacy, Raffles University, Neemrana - 301705.

[3] Professor, Department of Pharmaceutical Analysis, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Guntur, A.P., India - 522019.

[*] Corresponding Author: Syed Rihana, Assistant Professor, Department of Pharmaceutical Analysis, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Chandramoulipuram, Chowdavaram, Guntur – 522019, Andhra Pradesh, India. Email: rihanasyed687@gmail.com, Contact: +91-8008738481

Received: 15th Apr, 2026 | **Accepted:** 21st Apr, 2026 | **Available Online:** 24th Apr, 2026

ABSTRACT

Quality by Design (QbD) represents a systematic, science- and risk-based framework for pharmaceutical development that focuses on proactively embedding quality into products rather than relying exclusively on end-product testing. This approach involves the establishment of a Quality Target Product Profile (QTPP), followed by the identification of Critical Quality Attributes (CQAs), Critical Material Attributes (CMAs), and Critical Process Parameters (CPPs). A robust design space is subsequently defined using risk assessment methodologies and statistical tools, including Design of Experiments (DoE). Analytical Quality by Design (AQbD) extends these principles to analytical method development by introducing the concept of an Analytical Target Profile (ATP), ensuring that analytical procedures are reliable, robust, and fit for their intended purpose. Regulatory frameworks, particularly the guidelines issued by the International Council for Harmonisation (ICH Q8–Q14), support the implementation of QbD-based strategies and emphasize lifecycle management and continuous improvement. The integration of QbD and AQbD approaches contributes to enhanced product quality, reduced variability, improved cost-effectiveness, and strengthened regulatory compliance. Collectively, these methodologies play a pivotal role in the development of robust analytical methods aligned with contemporary pharmaceutical quality standards.

Keywords: Quality by Design (QbD); Analytical Quality by Design (AQbD); Quality Target Product Profile (QTPP); Critical Quality Attributes (CQAs); Critical Process Parameters (CPPs); Critical Material Attributes (CMAs); Analytical Target Profile (ATP); Design of Experiments (DoE); Design Space; Risk Assessment; ICH Guidelines (Q8–Q14); Method Development; Pharmaceutical Analysis; Lifecycle Management; Regulatory Compliance.

How to cite this article: Syed R, Kumar R, Vutla VR. A Structured Strategy for Pharmaceutical Analytical Method Development Based on Quality by Design (Qbd) and Analytical Quality by Design (Aqbd): Core Principles, Methodological Tools, and Regulatory Compliance Considerations. Int J Drug Deliv Technol. 2026;16(30s):871-883. DOI: 10.25258/ijddt.16.30s.87

Source of support: Nil.

Conflict of interest: The authors declare no conflict of interest.

INTRODUCTION:

Quality by Design (QbD) is a systematic approach to pharmaceutical development that begins with clearly defined objectives and emphasizes comprehensive understanding of both product and process, along with effective process control. This approach is firmly grounded in scientific principles and quality risk management[1,2]. A central tenet of QbD is that quality cannot be ensured solely through end-product testing but must be inherently built into the product during its design and development stages[2,3].Within the QbD framework, the design space is defined as the multidimensional range of input variables and process parameters—including materials, equipment, and operational conditions within which consistent product quality can be assured. Establishing and thoroughly understanding this design space prior to regulatory approval[1,4] is essential for ensuring product consistency and compliance[4,5]. The pharmaceutical industry, being one of the most highly regulated sectors, is tasked with delivering safe and efficacious drug products that achieve the intended therapeutic outcomes. Despite stringent regulatory oversight, the industry has faced persistent challenges in maintaining consistent product quality[3-6]. The concept of pharmaceutical quality itself has often been subject to varying interpretations. According to the U.S. Food and Drug Administration (FDA), pharmaceutical quality is achieved when a product consistently delivers the clinical performance specified in its labeling, is free from harmful contaminants, and is manufactured using a robust and controlled process[7].

In response to these challenges, the FDA introduced the QbD paradigm in the early 2000s, recognizing that increasing reliance on end-product testing alone is insufficient to ensure quality[7,8]. Instead, quality must be systematically integrated into product and process design. Within this context, quality is defined as the suitability of a product for its intended use, encompassing critical attributes such as identity, strength, and purity[2-6].The implementation of QbD has led to a paradigm shift in pharmaceutical development, promoting the use of scientific methodologies and risk-based approaches to enhance product quality[1,3]. Regulatory agencies have further supported this transition by issuing QbD-related guidance for various dosage forms, including immediate- and modified-release products, as well as biotechnological formulations[8,9]. In addition, international regulatory bodies advocate adherence to the International Council for Harmonisation (ICH) guidelines specifically Q8, Q9, Q10, and Q11—to advance quality practices and ensure consistent manufacturing standards across the pharmaceutical industry [4,5].

Origins and Evolution of Quality by Design (QbD):

Table .1: Key Milestones in the Historical Development of Quality by Design (QbD)

Year	Event / Milestone	Regulatory / Organizational Context
1950s	Conceptual foundations of QbD emerge	Early developments in quality management principles[11]
1970s	Formal development of QbD philosophy	Joseph M. Juran articulates quality principles shaping QbD[12]
Sep 2002	FDA incorporates QbD into cGMP	Shift from end-product testing to proactive, design-based quality[13]
2003–2004	Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach report	Supports QbD adoption; finalized in 2004[14]
2004	Introduction of Process Analytical Technology (PAT)	Integration of advanced analytical tools in development & manufacturing[15]
2005	EMA publishes Roadmap *to* 2010	Outlines future regulatory strategies[16]
2005	ICH Q8 (Pharmaceutical Development)	Establish scientific and risk-based framework for

	and Q9 (Quality Risk Management)	pharmaceutical development[17]
2008	ICH Q10 (Pharmaceutical Quality System)	Reinforces quality systems framework[18]
2009	ICH Q8(R2) updated guideline	Further refinement of QbD principles[19]
2011	FDA process validation guidance	Emphasis on practical QbD implementation[20]
2011	FDA-EMA pilot for parallel QbD submission assessment	Harmonization of regulatory review[21]
2012	Introduction of Real-Time Release Testing (RTRT)	In-process quality assurance during manufacturing[22]
2012	FDA guidance on QbD in ANDAs and drug substance development	Illustrates practical application of QbD principles[23]
2014	FDA updated process validation guidance	Clarifies regulatory expectations for QbD implementation[24]
2017	ICH proposes Q14 guideline	Harmonizes analytical method development[25]
2018	MHRA integrates QbD into UK regulations	Expands global adoption of QbD principles[26]
2020	ICH Q14 formally adopted	Comprehensive guidance on analytical method development[27]
2021	ICH Q14 finalized	Ensures harmonized and reliable analytical practices worldwide[28]

The AQbD Framework Typically Involves the Following Structured Steps:

1. **Definition of the Analytical Target Profile (ATP)[29,30]:** Establish the desired performance criteria for the analytical method, including accuracy, precision, specificity, sensitivity, and robustness, aligned with the intended purpose of the method.
2. **Identification of Critical Method Attributes (CMAs):** Determine the analytical parameters that have a direct impact on method performance, such as chromatographic conditions, detection settings, and sample preparation variables[31,32].
3. **Risk Assessment:** Use systematic risk management tools to prioritize factors influencing method performance, identifying which variables require careful control and optimization[33].
4. **Design of Experiments (DoE):** Apply statistical experimental designs to evaluate the effect of multiple variables simultaneously, facilitating method optimization and establishing the method's design space[35,37].
5. **Method Development and Optimization:** Utilize DoE outcomes to refine the analytical procedure, ensuring robustness and reproducibility under varied operational conditions[31,35].
6. **Establishment of Method Operable Design Region (MODR):** Define the range of method conditions within which the analytical procedure consistently meets ATP requirements, similar to the concept of design space in QbD[36].
7. **Control Strategy and Validation:** Implement a monitoring and control plan to maintain method performance throughout its lifecycle, and conduct method validation according to regulatory guidelines[29,37].
8. **Lifecycle Management:** Continuously monitor method performance, applying corrective actions as needed, and update the method in response to changes in analytical requirements or regulatory expectations[38].

By systematically applying AQbD, pharmaceutical analytical methods achieve greater robustness, reproducibility, and regulatory compliance, supporting consistent product quality and efficient lifecycle management. Regulatory frameworks, including ICH Q2(R2), Q8–Q14, endorse the adoption of AQbD principles to enhance analytical method reliability and assurance.

"Key Principles Underlying Analytical Quality by Design (AQbD)" [41,50.]

Analytical Quality by Design (AQbD) applies QbD principles to the systematic development of analytical methods, aiming to ensure robustness, reliability, and suitability for their intended purpose. The following key concepts are central to AQbD:

Analytical Target Profile (ATP): Defines the desired performance characteristics of an analytical method, including precision, accuracy, specificity, and robustness.

Critical Quality Attributes (CQA): Physical, chemical, biological, or microbiological properties that must be controlled to ensure product quality.

Critical Method Parameters (CMP): Analytical method variables that can influence the accuracy, precision, and reliability of results.

Critical Method Variables (CMV): Specific factors, such as temperature, time, or pH, that affect method performance.

Quality Target Product Profile (QTPP): Describes the desired quality attributes of the final pharmaceutical product.

Quality Target Method Profile (QTMP): Defines the objectives for an analytical method in terms of accuracy, precision, robustness, and suitability.

Critical Analytical Attributes (CAA): Characteristics of the analytical method that are essential for achieving the ATP.

Design of Experiments (DoE): A statistical approach used to systematically evaluate the impact of method variables and optimize method performance.

Method Operable Design Region (MODR): The defined range of method parameters within which the analytical procedure consistently meets the ATP requirements.

Quality Risk Management (QRM): A structured process for identifying, assessing, and controlling risks that may affect analytical method performance.

The integration of these concepts allows AQbD to achieve predefined analytical performance criteria, ensuring methods remain robust, accurate, and capable of delivering reliable results throughout the product lifecycle. The approach supports regulatory compliance, facilitates method validation, and enables continuous improvement in analytical quality.



Figure:1 Steps Involved In Analytical Quality By Design

Table .2: Key Elements of Analytical Quality by Design (AQbD)

AQbD Element	Definition	Purpose / Role	Key Considerations
Analytical Target Profile (ATP)	Defines the intended purpose and performance requirements of the analytical method.	Guides method selection, development, and validation; ensures alignment with QTPP.	Performance criteria: precision, accuracy, sensitivity, working range. Regulatory approval provides a benchmark for method suitability.
Critical Quality Attributes (CQA)	Physical, chemical, biological, or microbiological properties that must be controlled to ensure	Identifies method requirements impacting product safety, efficacy, and performance.	Focus on product attributes that influence analytical outcomes; impurities, degradation, potency.

	product quality.		
Critical Material Attributes (CMA)	Material properties (raw materials, intermediates, excipients) that affect CQAs.	Controls risks related to material variability impacting analytical performance.	Includes purity, particle size, composition, and stability; variations can affect method reliability.
Critical Process Parameters (CPP)	Process variables that significantly influence CQAs.	Ensures method consistency, reproducibility, and robustness.	Includes temperature, pH, time, pressure, and mixing; parameters identified via risk assessment.
Quality Risk Assessment (QRA)	Systematic evaluation of risks associated with CMAs and CPPs.	Detects potential issues early and mitigates risks to ensure product quality.	Uses structured tools (FMEA, Ishikawa diagrams) to prioritize control strategies and optimize method performance.

Risk Assessment in Analytical Quality by Design (AQbD):

The risk assessment process in AQbD is essential for identifying, evaluating, and mitigating potential factors that may affect product quality or analytical method performance. Several systematic approaches are employed during the **Risk Identification** phase, including Central Composite Design (CCD), Box-Behnken Design, and the Fishbone (Ishikawa) Diagram.

1. Risk Identification Using Central Composite Design (CCD):

Central Composite Design (CCD) is a widely used **Design of Experiments (DoE)** approach in pharmaceutical development for evaluating the influence of multiple process parameters on Critical Quality Attributes (CQAs). CCD combines a factorial or fractional factorial design with additional axial points and center points to explore linear, quadratic, and interaction effects between factors.

Axial Points: These are extreme values outside the standard factor range, facilitating the exploration of non-linear relationships and interactions that may not be apparent in conventional factorial designs.

Center Points: Replicated measurements at the central values of factors provide an estimate of experimental error and baseline performance, ensuring method consistency under nominal conditions.

By systematically varying process parameters, CCD enables identification of **Critical Process Parameters (CPPs)** and their quantitative impact on CQAs, highlighting potential sources of variability that must be controlled to maintain product quality and method robustness.

2. Risk Identification Using Box-Behnken Design:

The Box-Behnken design is a **three-level statistical DoE** used for evaluating the relationship between input factors, such as Critical Material Attributes (CMAs) and CPPs, and output responses, primarily CQAs. This method is particularly valuable in AQbD for risk identification and optimization of analytical and manufacturing processes.

Three-Level Design: Each factor is tested at low, medium, and high levels, providing detailed insight into parameter effects without requiring the full complexity of a factorial design.

Efficiency and Balance: The design reduces the number of experimental runs while maintaining sufficient data for robust analysis, making it cost-effective and practical.

Avoidance of Extreme Combinations: Box-Behnken design excludes impractical factor combinations, minimizing operational risk while allowing for the study of interactions.

The approach facilitates identification of the **most influential CPPs** affecting CQAs, guiding targeted process optimization.

3. Risk Identification Using Fishbone (Ishikawa) Diagram:

The Fishbone Diagram, also known as the Ishikawa or Cause-and-Effect Diagram, is a qualitative tool for systematically identifying potential risks and their root causes during AQbD development.

The **"head"** of the diagram represents the problem or undesired outcome, such as deviations in CQAs or analytical method failure.

The **"bones"** categorize potential causes, commonly including:

Materials: Variability in drug substances or excipients.

Methods/Processes: Analytical or manufacturing steps that could influence quality.

Equipment: Instrumentation and operational conditions.

Environment: External factors such as temperature, humidity, or contamination.

Personnel: Operator expertise and procedural adherence.

By visually mapping potential sources of variability, the Fishbone Diagram supports comprehensive risk identification and provides a foundation for subsequent quantitative risk assessment and mitigation strategies.

Design Space, Control Strategy, and Continual Improvement in Quality by Design (QbD):

1. Design Space

According to ICH Q8 guidance, the **Design Space** is defined as "the multidimensional combination and interaction of input variables and process parameters that have been demonstrated to assure quality." The Design Space represents the operational ranges of Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) within which a product can be consistently manufactured to meet predefined quality attributes. Importantly, operation within the Design Space is not considered a regulatory change, whereas movement outside this space typically triggers a post-approval change process.

The Design Space can be considered a subset of the broader **Knowledge Space**, which encompasses the full spectrum of process understanding. It is commonly represented using mathematical and graphical models to provide regulators with a visual depiction of permissible process ranges that ensure product quality. The Design Space can be defined at different manufacturing scales:

1. Laboratory-scale Design Space
2. Pilot-scale Design Space
3. Commercial-scale Design Space

Among these, the **Commercial-scale Design Space** is most relevant from a regulatory perspective, as it defines the operational limits for production at scale. Within the Design Space, a narrower **Control Space** may be defined for tighter in-house management of process parameters, although it does not carry regulatory significance.

2. Control Strategy:

A **Control Strategy** is a structured framework designed to ensure that product quality is consistently maintained throughout manufacturing. It comprises monitoring systems, specifications, and operational controls that maintain process performance within the defined Design Space. Critical process parameters and attributes identified through risk assessment are carefully monitored, with high-risk factors receiving additional controls as necessary. A robust control strategy ensures process stability, mitigates deviations, and maintains consistent product quality.

3. Continual Improvement:

Continual Improvement is a core principle of QbD, relying on ongoing risk review, effective communication, and collaboration among departments such as Plant Operations, Quality Assurance (QA), Quality Control (QC), Regulatory Affairs (RA), Research & Development (R&D), and Analytical R&D (AR&D) [39].

Continual Risk Review: Regularly reassessing risks using updated data, prior knowledge, and statistical design methods to refine processes.

Continual Method Monitoring (CMM): Continuous tracking of analytical method performance using control charts, system suitability data, and investigations to detect deviations before they impact product quality.

The feedback loop established by CMM ensures alignment between the **Design Space**, **Method Operable Design Region (MODR)**, and **Control**

Space, facilitating iterative improvements in process consistency and product quality over time.

4. Strategy, CQA, and ATP Integration:

Once an analytical method is validated, ongoing monitoring ensures it continues to meet the **Analytical Target Profile (ATP)** and relevant **Critical Quality Attributes (CQAs)**. Unlike traditional static methods, the QbD lifecycle approach emphasizes continuous monitoring, feedback, and optimization. This dynamic approach ensures that methods remain robust, reliable, and capable of producing high-quality products throughout the entire lifecycle.

Table. 3: Comparison of Regulatory Perspectives: QbD vs. AQbD

Aspect	Quality by Design (QbD)	Analytical Quality by Design (AQbD)
Scope	Encompasses the entire product development process, including drug substance and drug product.	Focused specifically on the development and validation of analytical methods.
Regulatory Emphasis	Proactive approach to ensure product quality throughout the lifecycle; relies on scientific knowledge and risk assessment rather than solely on end-product testing.	Ensures analytical methods are robust, reliable, and capable of consistently measuring product quality attributes over the lifecycle.
Key Framework Components	DesignSpace: multidimensional region defining acceptable process parameters. - Quality Target Product Profile (QTPP): defines desired product characteristics. - Critical Quality Attributes (CQAs): properties that must be controlled to ensure product quality.	Analytical Target Profile (ATP): defines method purpose and performance criteria (precision, accuracy, sensitivity, robustness). - Critical Analytical Attributes (CAAs) or CQAs: critical method outputs that ensure analytical reliability. - Method Operable Design Region (MODR): operational range ensuring method performance.
Regulatory Flexibility	Operations within the approved Design Space are not considered a change; deviations outside trigger post-approval change processes.	Method improvements within the predefined ATP/MODR are permitted without regulatory re-approval, supporting continuous improvement.
Lifecycle Management	Emphasizes ongoing product quality monitoring, method adjustments, and process improvements over the product lifecycle.	Supports continual method monitoring (CMM) and iterative optimization to maintain method robustness and reliability.
Regulatory Flexibility	Operations within the approved Design	Method improvements within the

	Space are not considered a change; deviations outside trigger post-approval change processes.	predefined ATP/MODR are permitted without regulatory re-approval, supporting continuous improvement.
Lifecycle Management	Emphasizes ongoing product quality monitoring, method adjustments, and process improvements over the product lifecycle.	Supports continual method monitoring (CMM) and iterative optimization to maintain method robustness and reliability.

Role of QbD in Analytical Method Development [42]:

The development of analytical methods involves designing procedures to accurately and precisely measure pharmaceutical product attributes. Integrating QbD principles into this process ensures the creation of methods that are reproducible, reliable, and fit-for-purpose. By adopting a QbD approach, pharmaceutical companies can develop analytical methods capable of delivering consistent, high-quality results over time, even under varying conditions of raw materials, environmental factors, or process parameters.

A key element of QbD in analytical method development is the **Design Space**, a multidimensional framework that defines acceptable ranges for critical method performance attributes such as precision, accuracy, sensitivity, and robustness. Establishing these boundaries allows for method optimization while maintaining consistent product quality. Furthermore, linking product characteristics to analytical and process parameters provides a deeper scientific understanding of method behavior, facilitating risk management and method reliability.

QbD also supports **continual improvement** of analytical methods throughout the product lifecycle. By implementing ongoing performance monitoring, data analysis, and iterative refinement, pharmaceutical companies can proactively identify opportunities to enhance method performance. This lifecycle-based approach ensures methods remain robust, scientifically sound, and compliant with regulatory expectations, fostering adaptability and efficiency in pharmaceutical analysis [40].

"Integration of Analytical Quality by Design (AQbD) in the Manufacturing Process" [43]:

Analytical Quality by Design (AQbD) begins with the definition of the **Analytical Target Profile (ATP)**, which articulates the intended purpose and performance requirements of the analytical method. Establishing the ATP provides a clear benchmark for method development, guiding subsequent decisions regarding method design, optimization, and validation.A critical step following ATP definition is the thorough understanding of the analytical system. This involves identifying and evaluating **Critical Method Parameters (CMPs)**, which are the variables that can significantly influence method performance. CMPs are determined through systematic **risk assessment**, which evaluates the potential impact of various method factors on the **Critical Method Attributes (CMAs)**, such as precision, accuracy, sensitivity, and robustness.The **Design Space** is then defined as a multidimensional region encompassing the range of operating conditions under which the CMPs reliably produce the desired CMAs. Within this space, method parameters can be adjusted to maintain analytical performance, ensuring that results consistently meet predefined specifications. The Design Space therefore represents the operational boundaries within which the analytical method is robust, reliable, and capable of achieving its intended purpose.Throughout this process, scientific tools and data-driven techniques are essential for acquiring comprehensive knowledge of the method and its behavior. By applying Quality by Design principles, variability is minimized, method robustness is enhanced, and analytical processes become more efficient and reliable. AQbD thus integrates systematic understanding, risk management, and controlled flexibility to ensure that analytical methods support consistent, high-quality outcomes throughout the product lifecycle.

Key QbD Tools in Analytical Method Development:

1. Risk Assessment Tools

Techniques such as **Failure Mode and Effects Analysis (FMEA)** and the **Risk Priority Number (RPN)** are applied to systematically identify, evaluate, and prioritize potential risks associated with analytical methods. These approaches ensure that **Critical Method Parameters (CMPs)** and sources of variability are thoroughly characterized and effectively controlled, minimizing the likelihood of method failure or inconsistent results.

2. Design of Experiments (DoE):

The **Design of Experiments** provides a statistical framework for investigating the influence of multiple factors and their interactions on analytical method performance. By systematically varying process parameters, DoE enables optimization of analytical methods and identification of conditions that yield reliable, precise, and reproducible results.

3. Design Space:

Within the **QbD framework**, the **Design Space** defines a multidimensional range of operational conditions under which an analytical method performs consistently. It establishes acceptable boundaries for critical parameters, allowing control of variability while maintaining the desired quality and reliability of analytical outcomes.

4. Analytical Target Profile (ATP):

The **Analytical Target Profile** specifies the intended purpose, performance criteria, and quality requirements of an analytical method, encompassing attributes such as precision, accuracy, sensitivity, and robustness. Serving as a blueprint, the ATP links the method's capabilities to overall product quality, guiding method development and ensuring suitability for its intended application.

5. Control Charts:

Control charts are employed to continuously monitor method performance, providing ongoing assurance of stability, reproducibility, and compliance with predefined limits. These tools support the long-term robustness of analytical methods, ensuring they consistently deliver reliable results throughout the product lifecycle.

Integration and Outcomes

By systematically implementing these QbD tools, pharmaceutical developers can design analytical methods that are scientifically rigorous, regulatory-compliant, and robust. This integrated approach not only facilitates **continual method improvement** but also ensures consistent, high-quality analytical performance, supporting reliable assessment of product quality across the entire lifecycle.

Key Tools and Their Purpose in Analytical Quality by Design (AQbD). [44,47-49.]

In Analytical Quality by Design (AQbD), several tools and techniques are employed to ensure the development of robust and reliable analytical methods. These tools help minimize variability, ensure method reproducibility, and ensure that analytical methods are aligned with the intended quality of the product. Below are some of the key tools used in AQbD, along with their purpose:

1. **Analytical Target Profile (ATP):** The ATP is the starting point for AQbD and defines the desired performance characteristics of an analytical method. It specifies the method's goals, such as precision, accuracy, sensitivity, and robustness. The ATP aligns the method's design with the overall Quality Target Product Profile (QTPP) to ensure the method serves its intended purpose.

2. **Design of Experiments (DoE):** DoE is a systematic approach used to optimize analytical methods by analyzing the effects of multiple variables simultaneously. By conducting experiments where different parameters (such as temperature, pH, concentration, etc.) are varied, DoE helps identify the optimal conditions for method performance. This tool is used to explore Critical Method Parameters (CMPs) and their interactions, ensuring the robustness of the method.

3. **Risk Assessment Tools (e.g., FMEA, RPN)**: Risk assessment tools like Failure Mode and Effect Analysis (FMEA) and Risk Priority Number (RPN) are used to identify and evaluate potential risks in the method development process. These tools help prioritize which factors or variables need closer monitoring and control to avoid failure modes that could impact the method's accuracy or reliability.

4. Design Space: The Design Space defines the operational ranges within which an analytical method performs effectively. It represents the multidimensional region of acceptable variations in Critical Method Parameters (CMPs), ensuring that

the method consistently produces the desired Critical Method Attributes (CMAs). The Design Space offers flexibility in method development, allowing for adjustments within defined boundaries without regulatory re-approval.

5. Control Charts: Control charts are used to monitor the consistency and stability of the analytical method over time. They track performance data (e.g., method precision, accuracy) and help identify any deviations or trends that could indicate method drift or loss of control. Regular use of control charts ensures ongoing monitoring of method performance during routine testing.

6. Process Analytical Technology (PAT): Itis a framework that employs real-time monitoring and control of the analytical process during method execution. PAT allows for the continuous assessment of method performance, enabling real-time adjustments to ensure that the analytical method remains within the required specifications. This approach supports real-time release testing (RTRT) and helps optimize method performance while maintaining product quality.

7. Method Operable Design Region (MODR): TheMODR is the region within the Design Space where the method can be operated effectively to meet the desired CMAs. It identifies the operating ranges for Critical Method Variables (CMVs) that ensure robust performance. The MODR helps limit variability and ensures that the method remains reliable across different batches and conditions.These tools collectively support the AQbD framework by ensuring that analytical methods are scientifically sound, risk-managed, and capable of consistently delivering the desired product quality. They enable a proactive approach to method development, allowing for continuous improvement and flexibility within regulatory boundaries.

Design of Experiments (DOE)[45-46]**:** Design of Experiments (DOE) is a structured, systematic approach used to understand the relationship between factors (input variables) and the resulting outcomes of a process. In pharmaceutical processes, the input variables typically include raw material attributes (e.g., particle size) and process parameters (e.g., speed, time), while the outputs are the Critical Quality Attributes (CQAs) such as blend uniformity, tablet hardness, thickness, and friability.Given that each unit operation involves multiple input variables, output variables, and process parameters, it is impractical to experiment with all of them. Therefore, scientists rely on prior knowledge and risk management to identify the key factors that should be studied using DOE. The results from DOE allow for:

Table .4: Key Aspects of AQbD: Design Space, MODR, and Risk Management Tools:

Aspect	Description / Purpose	Application / Notes
Optimal Conditions Identification	Determination of critical factors that most influence **Critical Quality Attributes (CQAs)** and understanding interactions between variables	Once optimal conditions are established, the **Design Space** for **Critical Process Parameters (CPPs)** can be defined. Scale-up may require additional experiments, as some CPPs are scale-dependent. Prior knowledge allows leveraging past experiences to define critical material properties and processing ranges.
Method Operable Design Region	A multidimensional space based on method factors	MODR defines method controls such

(MODR)	and settings that ensures optimal method performance	as **System Suitability**, **Relative Response Time (RRT)**, and **Relative Response Factor (RRF)**. Verification ensures the method conforms to the **Analytical Target Profile (ATP)**, enabling consistent, robust, and reliable performance.
Risk Management Tools	Techniques for identifying, assessing, and controlling potential risks in pharmaceutical development and analytical methods	Includes: • **Flowcharts, Check Sheets, Cause-and-Effect Diagrams** – basic visualization tools • **Failure Mode and Effects Analysis (FMEA)** – evaluates potential failure modes • **Failure Mode, Effects, and Criticality Analysis (FMECA)** – adds criticality ranking • **Fault Tree Analysis (FTA)** – top-down deductive analysis • **Hazard Analysis and Critical Control Points (HACCP)** – preventive approach • **Preliminary Hazard Analysis (PHA)** – early hazard identification • **Risk Ranking and Filtering** – prioritization by likelihood and impact

Advantages of Quality by Design (QbD) in Pharmaceutical Development:

Quality by Design (QbD) is a systematic and proactive approach to pharmaceutical development that integrates quality into both the design of products and manufacturing processes from the outset. By focusing on **Critical Quality Attributes (CQAs)** and **Critical Process Parameters (CPPs)**, QbD enhances product reliability and reduces variability, leading to consistently high-quality products. This methodical approach enables better decision-making during development, empowers technical staff, and minimizes manufacturing issues. Furthermore, by incorporating QbD principles, pharmaceutical companies can achieve outcomes that extend beyond regulatory compliance, including cost savings, improved efficiency, and enhanced risk management.

Industry-Specific Advantages of QbD:

One of the key benefits of QbD in industry is the **elimination of post-approval modifications**. By defining the **Design Space**, manufacturers can operate within a well-characterized range of process conditions, reducing the need for regulatory submissions and modifications after product launch. This is particularly advantageous during the scale-up from laboratory to production environments, as prior knowledge of consistent technologies and excipients allows companies to leverage previous experience to define critical material and process parameters.

QbD also supports **continuous manufacturing**, which offers distinct advantages over traditional batch processing. Continuous processes streamline production timelines, allow flexible production volumes, improve product quality, and reduce manufacturing costs. Additionally, continuous manufacturing can help mitigate challenges such as drug shortages and product recalls. However, quality assurance remains complex in continuous systems due to disturbance propagation within integrated processes, emphasizing the need fc1. robust monitoring and control strategies.

Integration of Advanced Analytical Tools:

The incorporation of advanced analytical tool2. further enhances QbD implementation. Hig h throughput screening, omics technologie (genomics, proteomics, metabolomics), an3. sophisticated spectroscopic methods facilitate deeper understanding of CQAs and CPPs. Re a l time monitoring and data analytics enabl14. immediate adjustments and provide insights int complex variable interactions, allowing fo proactive control of product quality throughout th5. manufacturing process.

Enhanced Product and Process Performance:

By systematically addressing potential issue6. during the design and development phases, Qb l minimizes manufacturing problems and ensure smoother production processes. The proactive focu7. on CPPs and CQAs enables manufacturers t control product quality more effectively, reducin downtime and disruptions. Additionally, th integration of **Design Space** and **MODR (Metho** 8. **Operable Design Region)** concepts allow consistent method performance, risk mitigation, an continuous improvement across the product lifecycle.

CONCLUSION:

Quality by Design transforms analytical method development and pharmaceutical manufacturing by emphasizing preemptive quality integration rather than relying solely on end-product testing. The QbD framework enhances method reliability, robustness, and efficiency, enabling compliance with regulatory standards while facilitating continuous improvement. Its applications span a wide range of analytical techniques, including chromatography, spectroscopy, biopharmaceutical assays, and dissolution testing. By leveraging systematic experimentation, risk assessment, and real-time monitoring, QbD ensures that analytical methods and manufacturing processes are scientifically sound, robust, and capable of consistently delivering high-quality products. As pharmaceutical industries increasingly adopt QbD principles, these advantages will continue to drive innovation, efficiency, and global competitiveness.

REFERENCES:

Yu LX, Amidon G, Khan MA, et al. Understanding pharmaceutical quality by design. AAPS J. 2014;16(4):771–783.

International Council for Harmonisation (ICH). ICH Q8(R2): Pharmaceutical Development. Geneva: ICH; 2009.

Rathore AS, Winkle H. Quality by design for biopharmaceuticals. Nat Biotechnol. 2009;27(1):26–34.

International Council for Harmonisation (ICH). ICH Q9: Quality Risk Management. Geneva: ICH; 2005.

International Council for Harmonisation (ICH). ICH Q10: Pharmaceutical Quality System. Geneva: ICH; 2008.

Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: Concepts for ANDAs. AAPS J. 2008;10(2):268–276.

US Food and Drug Administration (FDA). Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach. Silver Spring, MD: FDA; 2004.

US Food and Drug Administration (FDA). Guidance for Industry: PAT—A Framework for Innovative Pharmaceutical

Development, Manufacturing, and Qualit Assurance. Silver Spring, MD: FDA; 2004.
9. US Food and Drug Administratio (FDA). Guidance for Industry: QbD fc ANDAs. Silver Spring, MD: FDA; 2012.
10. International Council for Harmonisatio (ICH). ICH Q11: Development and Manufacture c Drug Substances. Geneva: ICH; 2012.
11. Juran JM. Juran's Quality Control Handbook. Ne York: McGraw-Hill; 1951.
12. Juran JM. Quality Planning and Analysis. Ne York: McGraw-Hill; 1970.
13. US Food and Drug Administratio (FDA). Pharmaceutical cGMPs for the 21 Century: A Risk-Based Approach. Silver Sprin MD: FDA; 2002.
14. US Food and Drug Administration (FDA). Fin Report: Pharmaceutical cGMPs for the 21 Century – A Risk-Based Approach. Silver Sprin MD: FDA; 2004.
15. US Food and Drug Administratio (FDA). Guidance for Industry: PAT – Framework for Innovative Pharmaceutic Development, Manufacturing, and Qualit Assurance. Silver Spring, MD: FDA; 2004.
16. European Medicines Agency (EMA). Roadmap t 2010: Preparing the Ground for the Future. Londo EMA; 2005.
17. International Council for Harmonisatio (ICH). ICH Q8: Pharmaceutical Development; IC Q9: Quality Risk Management. Geneva: ICH; 200
18. International Council for Harmonisatio (ICH). ICH Q10: Pharmaceutical Quali System. Geneva: ICH; 2008.
19. International Council for Harmonisatio (ICH). ICH Q8(R2): Pharmaceutic Development. Geneva: ICH; 2009.
20. US Food and Drug Administratio (FDA). Guidance for Industry: Process Validation General Principles and Practices. Silver Sprin MD: FDA; 2011.
21. US Food and Drug Administration (FDA European Medicines Agency (EMA). Parall Assessment Pilot Program for Qbl Applications. 2011.
22. US Food and Drug Administratio (FDA). Guidance for Industry: Real-Time Releas Testing (RTRT). Silver Spring, MD: FDA; 2012.
23. US Food and Drug Administration (FDA). Guidance for Industry: QbD for ANDAs and Drug Substance Development. Silver Spring, MD: FDA; 2012.
24. US Food and Drug Administration (FDA). Updated Process Validation Guidance. Silver Spring, MD: FDA; 2014.
25. International Council for Harmonisation (ICH). ICH Q14: Analytical Procedure Development (Draft Guideline). Geneva: ICH; 2017.
26. Medicines and Healthcare products Regulatory Agency (MHRA). UK Regulatory Framework Incorporating QbD. London: MHRA; 2018.
27. International Council for Harmonisation (ICH). ICH Q14: Analytical Procedure Development. Geneva: ICH; 2020.
28. International Council for Harmonisation (ICH). ICH Q14: Analytical Procedure Development (Final Guideline). Geneva: ICH.
29. International Council for Harmonisation (ICH). ICH Q2(R2): Validation of Analytical Procedures. Geneva: ICH; 2023.
30. Montgomery DC. Design and Analysis of Experiments. 8th ed. New York: Wiley; 2013.
31. Box GEP, Behnken DW. Some new three-level designs for the study of quantitative variables. Technometrics. 1960;2(4):455–475.
32. Ishikawa K. Guide to Quality Control. Tokyo: Asian Productivity Organization; 1986.
33. United States Pharmacopeia (USP). General Chapter <1220>: Analytical Procedure Lifecycle. USP–NF.
34. Rozet A, et al. Analytical quality by design (AQbD): An overview. J Chromatogr A. 2013.
35. Borman PJ, et al. Development of analytical methods using AQbD. J Pharm Biomed Anal. 2007. (32)
36. McDowall RD. A risk-based approach to AQbD. LCGC North Am. 2013.
37. Orlandini S, et al. AQbD approach using DoE. Anal Chim Acta. 2014.
38. Ermer J. Quality by design in analytical methods. Pharm Technol. 2015.
39. Lawrence MS. Analytical quality by design (AQbD): A review. J Pharm Biomed Anal. 2014;102:159–167.

40. Sha'at M, Spac AF, Stoleriu I, et al. Implementation of QbD approach for estimation of metformin hydrochloride HPLC. Pharmaceutics. 2022;14(6):1187.
41. Aru PB, Gulhane MS, Katekar VA, Deshmukh SP. Quality by design (QbD) in pharmaceutical development: A comprehensive review. GSC Biol Pharm Sci. 2024;26(1):328–340.
42. Jadhav JB, Girawale NN, Chaudhari RA. QbD approach in pharmaceutical development. Int J Pure Appl Biosci. 2014;2(5):214–223.
43. Darkunde SL. A review on quality by design. Int J Pharm Chem Anal. 2018;5(1):1–6.
44. Pathirannahalage PH, Nabetani A, Kato S, et al. Determining low-risk setpoints in continuous manufacturing. Int J Pharm. 2025;682:125922.
45. Bairagi A, Kothrukar R, Chikhale H, et al. AQbD – a novel strategy for analytical methods. Future J Pharm Sci. 2024;10:138.
46. Ameen SA, Pappula N. Analytical QbD approach in pharmaceuticals. J Pharm Res. 2023;22(4):178–185.
47. Charde MS, Jatte KP, Masne DD, et al. QbD in analytical method development. Int J Pharm Pharm Res. 2021;21(2):238–256.
48. Gholve SB, Ajgunde RR, Bhusnure OG, et al. Analytical method development using QbD. Der Pharm Sin. 2015;6(8):18–24.
49. Katekar V, Sangule D, Bhurbhure O, et al. QbD approach in analytical methods. J Drug Deliv Ther. 2022;12(3-S):255–261.
50. Beg S, Hasnain MS, Rahman M, Swain S. Introduction to quality by design (QbD). In: Beg S, Hasnain MS, Rahman M, Swain S, editors. Pharmaceutical Quality by Design. New York: Elsevier; 2019. p. 1–17.